STOCK TITAN

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq: LAB) completes merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research. The combined company has a formidable capital structure comprising over $500 million in cash and cash equivalents, aiming to self-fund future growth initiatives. The company is targeting large, high growth markets with a diverse portfolio of life sciences tools and is expected to realize $80 million in annual cost synergies by 2026. Key leadership team appointments have also been made.
Positive
  • None.
Negative
  • None.

The merger between Standard BioTools Inc. and SomaLogic represents a significant consolidation within the life sciences tools sector, which is currently experiencing a wave of mergers and acquisitions. This consolidation is driven by the need to offer comprehensive multi-omic technologies that can cater to the rapidly evolving demands of biomedical research and personalized medicine. The transaction structure, where SomaLogic stockholders receive 1.11 shares of Standard BioTools common stock for each share owned, indicates a strategic move to align interests and incentivize continued investment into the merged entity.

The combined company's focus on leveraging $500 million in cash and cash equivalents to self-fund growth initiatives is a strong indication of its financial health and commitment to long-term value creation. The estimated $80 million in annual cost synergies by 2026 suggests a robust plan for operational efficiency and profitability. A critical factor for investors to watch will be the company's ability to realize these synergies without disrupting the ongoing research and product development efforts.

The completion of the merger between Standard BioTools and SomaLogic has immediate implications for the stock market, as it eliminates SomaLogic's stand-alone trading on the NASDAQ Global Select Market. This move is likely to concentrate investor focus on Standard BioTools' performance. The company's expanded commercial reach and cross-selling opportunities through its diversified portfolio could potentially lead to an enhanced revenue stream. However, investors should be cautious and seek to understand how the integration of these two companies will affect the combined company's market position, especially considering the competitive nature of the life sciences tools industry.

From a financial perspective, the ability of Standard BioTools to utilize its capital structure to fund future growth is a positive sign for its financial management and strategic planning. However, the true test will be in the execution of these initiatives and the market's reception of the combined company's offerings. The impact on the stock will depend on the company's performance against the anticipated cost synergies and revenue growth resulting from the merger.

The merger's emphasis on multi-omic technologies is a testament to the growing importance of integrating various omics data (genomics, proteomics, metabolomics, etc.) in life sciences research. The combined company's strategy to expedite scale and profitability through enhanced throughput and data quality can significantly advance research capabilities. For stakeholders in the biomedical sector, this could translate into accelerated discovery and development timelines for new therapeutics and diagnostics.

Moreover, the cross-selling opportunities and the potential for expanding commercial reach are not just business strategies but also reflect the company's ambition to facilitate a broader adoption of multi-omic approaches in research. The long-term success of this merger will hinge on the combined company's ability to integrate their technologies seamlessly and deliver on the promise of high-quality, high-throughput multi-omic data that can drive innovation in health sciences.

Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that it has completed its merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research.

Each SomaLogic stockholder will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. SomaLogic common stock and public warrants have ceased trading and will no longer be listed on the NASDAQ Global Select Market.

“This is an exciting day as we officially bring together the innovative multi-omic technologies and incredible talent of Standard BioTools and SomaLogic to create one company that is a diversified leader in life sciences tools,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We are moving forward with a significantly expanded and diversified platform, greater financial flexibility and an accelerated path to profitability. As a larger well-capitalized company, we have greater capacity to self-fund future growth initiatives and accelerate research insights across the industry, better serving our customers and delivering sustainable long-term growth for our shareholders. We are focused on ensuring a smooth transition and achieving our stated commitments.”

The combined company is poised to realize significant benefits as a multi-omic technology leader, targeting large, high growth markets with a diverse portfolio of life sciences tools that power industry-leading throughput and data quality. The combined company is moving forward focused on:

  • Expanding its commercial reach and maximizing cross-selling opportunities through complementary offerings and end markets.
  • Expediting scale to create an accelerated path to profitability with an estimated $80 million in annual cost synergies to be realized by 2026[1].
  • Self-funding future growth initiatives through its formidable capital structure comprising over $500 million in cash and cash equivalents.
  • Delivering additional meaningful value creation opportunities through a proven model that couples deep large-enterprise life sciences expertise and operating discipline.

Board and Leadership Team Appointments

As previously announced, in connection with the closing of the merger, Michael Egholm, Jeff Black and Alex Kim will continue to serve as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of Standard BioTools, respectively. Adam Taich, SomaLogic’s Interim Chief Executive Officer, has been appointed as Chief Strategy Officer of Standard BioTools and Shane Bowen, SomaLogic’s Chief Research and Development Officer, has been appointed as Chief Technology Officer of Standard BioTools.

Tom Carey, Troy Cox and Kathy Hibbs have joined the Standard BioTools Board of Directors and Mr. Carey has been appointed as Chairman of the Board. Carlos Paya, Laura Clague and Martin Madaus – who served on the Standard BioTools Board until the closing of the merger – have resigned from the Standard BioTools Board.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, guidance, including related to revenues, margin, and operating expenses, and statements regarding future financial performance and expectations, operational and strategic plans, deployment of capital, our cash runway and sufficiency of cash resources, potential M&A activity, market and growth opportunity and potential, and the potential to realize the benefits following the merger. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, the outcome of any legal proceedings related to the merger; risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; risks that we may not realize expected cost savings from our restructuring, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on our development activities and results of operation; restructuring activities, including our subleasing plans, customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause us to use cash more quickly than we expect or change or curtail some of our plans, or both; risks that our expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in Standard BioTools’ business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to Standard BioTools’ research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 14, 2023 and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 28, 2023 and in SomaLogic’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law. 

Contacts

Investors

Peter DeNardo
CapComm Partners
ir@standardbio.com

Media

Nick Lamplough / Dan Moore / Tali Epstein
Collected Strategies
LAB-CS@collectedstrategies.com


1 Compared to annualized run-rate based on 1H 2023 results. Total cost synergies exclude non-cash, restructuring-related, transaction-related and other non-recurring costs for both Standard BioTools and SomaLogic.


FAQ

What is the ticker symbol of Standard BioTools Inc.?

The ticker symbol of Standard BioTools Inc. is LAB.

What is the purpose of the merger between Standard BioTools and SomaLogic?

The merger aims to create a leading provider of differentiated multi-omics tools for research, targeting large, high growth markets with a diverse portfolio of life sciences tools.

What is the estimated annual cost synergies to be realized by the combined company?

The combined company is expected to realize $80 million in annual cost synergies by 2026.

What are the key leadership team appointments made after the merger?

Michael Egholm continues to serve as Chief Executive Officer, Jeff Black as Chief Financial Officer, and Alex Kim as Chief Operating Officer of Standard BioTools. Adam Taich has been appointed as Chief Strategy Officer, and Shane Bowen as Chief Technology Officer.

Standard BioTools Inc.

NASDAQ:LAB

LAB Rankings

LAB Latest News

LAB Stock Data

977.46M
50.24M
0.69%
56.05%
2.67%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About LAB

fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.